Successful Drug Discovery. Volume 1 /
The first volume of the book series ""Successful Drug Discovery"" isfocusing on new drug discoveries during the last decade, fromestablished drugs to recently introduced drugs of all kinds:small-molecule-, peptide-, and protein-based drugs. The role of serendipity is analyzed in...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Weinheim, Germany :
Wiley-VCH,
[2015]
|
| Subjects: | |
| Online Access: | CONNECT |
Table of Contents:
- Cover; Related Titles; Title Page; Copyright; Advisory Board Members; Preface; Part I: General Aspects; Part II: Drug Class; Part III: Case Histories; Chapter 1: Serendipitous Target-Based Drug Discoveries; 1.1 Introduction; 1.2 Recent Examples of Target-Based Drug Discovery; 1.3 Serendipitous Target-Based Drug Discoveries; 1.4 Drospirenone (Contraceptive with Anti-aldosterone Activity); 1.5 Escitalopram (Selective Serotonin Reuptake Inhibitor Antidepressant); 1.6 Ezetimibe (Inhibitor of Cholesterol Absorption); 1.7 Lamotrigine (Discovery of a Standalone Drug for the Treatment of Epilepsy).
- 1.8 Omeprazole (Proton Pump Inhibitor Acid-Suppressive Agent)1.9 Outlook; Acknowledgments; List of Abbreviations; References; Chapter 2: Drug Discoveries and Molecular Mechanism of Action; 2.1 Introduction; 2.2 Mechanistic Paradox; 2.3 Molecular Mechanism of Action; 2.4 How MMOAs were Discovered; 2.5 Case Study: Artemisinin; 2.6 Summary; List of Abbreviations; References; Chapter 3: Insulin Analogs
- Improving the Therapy of Diabetes; 3.1 Introduction; 3.2 Pharmacology and Insulin Analogs; 3.3 Chemical Description; 3.4 Rapid-Acting Insulin Analogs (Prandial or Bolus Insulin).
- 3.5 Long-Acting Insulin Analog Formulations (Basal Insulin)3.6 Conclusions and Future Considerations; List of Abbreviations; References; Chapter 4: The Discovery of StendraTM (Avanafil) for the Treatment of Erectile Dysfunction; 4.1 Introduction; 4.2 Discovery of Avanafil; 4.3 Pharmacological Features of Avanafil; 4.4 Clinical Studies of Avanafil; 4.5 Conclusion; List of Abbreviations; References; Chapter 5: Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes; 5.1 Introduction; 5.2 Role of SGLT2 Transporters in Renal Function; 5.3 O-Glucoside SGLT2 Inhibitors.
- 5.4 m-Diarylmethane C-Glucosides5.5 Profiling Studies with Dapagliflozin; 5.6 Clinical Studies with Dapagliflozin; 5.7 Summary; List of Abbreviations; References; Chapter 6: Elvitegravir, A New HIV-1 Integrase Inhibitor for Antiretroviral Therapy; 6.1 Introduction; 6.2 Discovery of Elvitegravir; 6.3 Conclusion; List of Abbreviations; References; Chapter 7: Discovery of Linagliptin for the Treatment of Type 2 Diabetes Mellitus; 7.1 Introduction; 7.2 Discovery of Linagliptin
- High Throughput Screening Hit Optimization.
- 7.3 Rationalization of DPP-4 Inhibition Potency by Crystal Structure Analysis and Studies of Binding Kinetics7.4 Basic Physicochemical, Pharmacological, and Kinetic Characteristics; 7.5 Preclinical Studies; 7.6 Clinical Studies; 7.7 Conclusion; List of Abbreviations; References; Chapter 8: The Discovery of Alimta (Pemetrexed); List of Abbreviations; References; Chapter 9: Perampanel: A Novel, Noncompetitive AMPA Receptor Antagonist for the Treatment of Epilepsy; 9.1 Introduction; 9.2 Seeds Identification by High Throughput Screening (HTS) Assays.
